Loading
A phase 1/2 trial of Capecitabine in advanced solid tumours, run by Beijing Biostar Pharmaceuticals Co., Ltd., active and no longer recruiting.
Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05700084 by Beijing Biostar Pharmaceuticals Co., Ltd., with 84 participants enrolled, started 2023-06-09 and due to reach its primary completion in 2025-10-08. Interventions recorded: Utidelone Capsule (Part 1), Drug A Utidelone Capsule (Part 2: Group A-B), Drug A Utidelone Capsule (Part 2: Group B-A), Drug B Utidelone Injection (Part 2: Group A-B), Drug B Utidelone Injection (Part 2: Group B-A) and Capecitabine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Biostar Pharmaceuticals, Utidelone, Capecitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Capecitabine, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Capecitabine, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Capecitabine, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/